A federal court denied the FTC's request to block GTCR's $627 million acquisition of Surmodics, allowing the merger to proceed despite initial regulatory challenges related to medical device coating competition.

The biocompatible coating market is expected to grow significantly due to increased demand for medical implants and devices, advancements in nanotechnology, and rising prevalence of chronic diseases requiring medical interventions.

Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.

The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.